anti-mKRAS/HLA class I TCR T-cell therapy (Penn Medicine)

N/A

Report date: 2025/03/18 18:02:00

Base Information

Drug Nameanti-mKRAS/HLA class I TCR T-cell therapy (Penn Medicine)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulatorsHistocompatibility antigens class I modulators

TargetsHistocompatibility antigens class IGTPase KRas

Therapy Area/IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPenn Medicine

China Registration ClassN/A

Develop Information

Active CompaniesPenn Medicine

Inactive CompaniesN/A

Active IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A